Arvinas Inc

Overview

Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of pro-inflammatory, cancer, autoimmune and rare diseases. Its proprietary approach is to target disease causing proteins. Arvinas’s protein degradation technology platforms include proteolysis-targeting chimera and hydrophobic tagging which induce the loss of intracellular proteins. The company intends to expand its transformative protein degradation technology and its product candidates into clinical development through collaborations. It also develops degraders for targets in cancer, including androgen receptor, estrogen receptor and BET proteins. Arnivas is headquartered in New Haven, Connecticut, the US.
Key Stats
Address
5 Science Park, NEW HAVEN, Connecticut
Headquarters

United States of America

Contact

1 203 5351456

Website
arvinas.com
No of Employees

179

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

ARVN [NASD]

Revenue (2020)

$22 m

-48.8% (2020 vs 2019)
Net Income (2020)

$-119 m

-69.3% (2020 vs 2019)
Net Profit Margin

-547 %

-234.7% (2020 vs 2019)
Market Cap *

$4,520 m

EPS *

$-3

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Arvinas Inc
Key Information
Headquarters United States of America
Headquarter City NEW HAVEN
Headquarter State/Province Connecticut
No. of Employees 179
Entity Type Public

Products & Services

Arvinas is a manufacturer of therapeutic products. The key products of the company include the following:

Products
  • Protein Degradation Therapeutics
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In July, the company and Pfizer entered into a collaboration to develop and commercialize ARV-471,…
2018 Stock Listings/IPO In September, the company announced its plans to raise IPO of shares for US$107 million.
2015 Contracts/Agreements The company signed strategic collaboration with Merck, where the company's novel PROTAC technology will be…
2015 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Arvinas Androgen Receptor, Inc.
Arvinas BRD4, Inc.
Arvinas Estrogen Receptor, Inc.
Arvinas Operations, Inc.
Arvinas Winchester, Inc.

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
09 Aug 2021 Insilico Medicine Enters into R&D Collaboration with Arvinas Partnership InSilico Medicine Inc; Arvinas Inc
22 Jul 2021 Arvinas to Raise USD350 Million in Private Placement of Shares Equity Offering Pfizer Inc Arvinas Inc
22 Jul 2021 Arvinas and Pfizer Enter into Collaboration Partnership Pfizer Inc; Arvinas Inc
14 Dec 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
27 Feb 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
06 Nov 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

34

Active Jobs

29

Posted

26

Closed

Job Trends

Latest Jobs

Job title Company Country
Development Team Leader Arvinas Inc United States
Associate Director, Early Commercial Development Arvinas Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar